French registry for rifampicin-resistant tuberculosis
Part of Infections clinical trials.
This study is creating a national registry of people in France who have rifampicin-resistant tuberculosis (MDR/RR-TB). It will help doctors understand the disease better and improve care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are receiving treatment for rifampicin-resistant or multidrug-resistant tuberculosis (MDR/RR-TB).
- If you were treated in the Paris region (at certain hospitals) before this study started, you may be eligible for the retrospective part.
- If you are being treated anywhere in France now or in the future, you may be eligible for the prospective part.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a 6-month treatment for people with rifampicin-resistant tuberculosis (TB). It aims to see if a shorter, simpler regimen works as well as longer treatments. You may qualify if you have this type of TB and meet a few health requirements.
This study follows people starting treatment for tuberculosis (TB) in France to learn more about the disease and its treatment. If you have been diagnosed with TB and started treatment within the last 8 days, you may be able to join.
This trial is a national hospital registry that collects information from people hospitalized with suspected infective endocarditis (an infection of the heart lining or valves). It may help doctors better classify cases and improve care by analyzing real-world patient data.
This trial tests a personalized treatment approach for people with rifampicin-resistant TB that is still sensitive to fluoroquinolones. It aims to find the best combination of medicines based on your specific TB profile.
This study follows people who are newly treated for tuberculosis, including lung and non-lung (extra-lung) cases. It may help doctors better understand tuberculosis and how patients respond after treatment starts.
This study is a registry that collects information from adults with tuberculosis in Europe. It helps researchers better understand the disease and improve care.
Hear when a new Rifampicin-resistant Tuberculosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.